KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Receivables: 2009-2025

Historic Receivables for Novavax (NVAX) over the last 11 years, with Sep 2025 value amounting to $47.0 million.

  • Novavax's Receivables fell 56.77% to $47.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $466.1 million, marking a year-over-year decrease of 6.01%. This contributed to the annual value of $121.4 million for FY2024, which is 61.56% down from last year.
  • As of Q3 2025, Novavax's Receivables stood at $47.0 million, which was down 80.34% from $239.4 million recorded in Q2 2025.
  • Novavax's Receivables' 5-year high stood at $530.5 million during Q1 2022, with a 5-year trough of $29.3 million in Q1 2024.
  • Its 3-year average for Receivables is $161.7 million, with a median of $121.4 million in 2024.
  • In the last 5 years, Novavax's Receivables surged by 579.57% in 2021 and then slumped by 90.91% in 2024.
  • Novavax's Receivables (Quarterly) stood at $490.3 million in 2021, then plummeted by 74.54% to $124.8 million in 2022, then soared by 152.96% to $315.7 million in 2023, then plummeted by 61.56% to $121.4 million in 2024, then slumped by 56.77% to $47.0 million in 2025.
  • Its Receivables stands at $47.0 million for Q3 2025, versus $239.4 million for Q2 2025 and $58.3 million for Q1 2025.